Chemomab Therapeutics Ltd's Customers Performance

Name: Chemomab Therapeutics Ltd Customers by Division and Industry - CSIMarket
Creator: CSIMarket.com
License: https://csimarket.com/help/terms-of-use

CMMB

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.


CMMB's Source of Revenues		• List of CMMB Customers

for the same period Chemomab Therapeutics Ltd

• List of CMMB Customers

Select the Relationship:

Customers ▼

Select the Category:

Comparison ▼

Customers ▼

Basic Report▼

Chemomab Therapeutics Ltd's Comment on Sales, Marketing and Customers

News about Chemomab Therapeutics Ltd Contracts

Chemomab Therapeutics Drives Forward with Positive Q3 Outcomes and Strategic Milestones Anticipated in Early 2025,

Chemomab Therapeutics: Q3 2024 Financial Results and Corporate Progress Highlights Chemomab Therapeutics, a clinical-stage biotechnology company focused on developing innovative therapeutics for fibrotic and inflammatory diseases with high unmet medical needs, has released its third-quarter 2024 financial results and provided a substantial corporate update. Financial Overview: In the third quarter of 2024, Chemomab has strategically managed its resources to advance its clinical pipeline. While specific financial figures were not disclosed in the provided materials, the nature of their ongoing development projects suggests an ongoing investment in research and development, consistent with the typical financia...

CCL24-Neutralizing Antibody CM-101 Shows Promise in Alleviating Disease Progression and Severity in Primary Scle...

Chemomab Therapeutics has recently published two significant articles that highlight the clinical potential of their CCL24-neutralizing antibody, CM-101. These publications reinforce the role of CCL24 in primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc), shedding light on its impact on disease progression, severity, and mortality. 1: Chemomab Therapeutics Announces New Publications Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing CholangitisThe first publication by Chemomab Therapeutics focuses specifically on the role of CCL24 in primary sclerosing cholangitis (PSC). PSC is a chronic liver disease characterized by inflammation and fibrosis of...

Chemomab's CCL24 Target Proven Crucial in Systemic Sclerosis: Groundbreaking Peer-Reviewed Study Validates Link to Disease Severity and Mortality, Ignites Hope for Transformative Therapies

Systemic sclerosis is characterized by the abnormal production and accumulation of collagen, leading to fibrosis and tissue damage. The disease often progresses slowly but can cause significant disability and impact the overall quality of life. With limited treatment options available, the discovery of new therapeutic targets has become paramount in improving patient outcomes.Chemomab has been at the forefront of research and development efforts aimed at finding novel solutions for SSc. Through their rigorous scientific approach, they have identified CCL24, a chemokine associated with inflammation and tissue fibrosis, as a promising target for intervention. This recent peer-reviewed publication serves as an ...

CMMB's Stock Performance relative to it's Customers

CMMB's vs. Customers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)

COMPANY NAME	MARKET CAP	REVENUES	INCOME	EMPLOYEES
Chemomab Therapeutics Ltd	1,382.72	0.00	9.00	12
SUBTOTAL	0.00	0.00	0.00	-

Sources: Chemomab Therapeutics Ltd’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Chemomab Therapeutics Ltd’s corporate clients.
For your research, we’ve provided 9 tables on Chemomab Therapeutics Ltd corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.